Showing results (481-490 of 586) with videos related to
Sort By:
Pageof 59
The American Journal of Cardiology|November 7, 2009
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY)Jason P Linefsky, Min Lin, Karen S Pieper, et al.Circulation|September 15, 2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialDavid Aguilar, Scott D Solomon, Lars Køber, et al.American Heart Journal|December 22, 2005
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trialsJohn M Galla, Kenneth W Mahaffey, Shelly K Sapp, et al.Circulation|November 23, 2005
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Harvey D White, Philip E G Aylward, Zhen Huang, et al.International Journal of Cardiology|November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.JACC. Heart Failure|October 14, 2019
Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HFStephen J Greene, Adam D DeVore, Shubin Sheng, et al.Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.Journal of the American Heart Association|September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.Circulation. Heart Failure|February 8, 2013
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research studyYee Weng Wong, Laine Thomas, Jie-Lena Sun, et al.American Heart Journal|December 5, 2009
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registryTelly A Meadows, Deepak L Bhatt, Alan T Hirsch, et al.Pageof 59